In summary, our finding suggested that UTMD enhances the immunity in the late-stage tumor by targeting the CEC, and the combination of UTMD and PDL-1/PD-1 blockade therapy will be a promising therapeutic strategy for cancer treatment. This evidence concerns the gene CD274 and cancer.